Loading…
Based on limited metadata, this FDA Warning Letter was issued to Innovative Intrathecal Solutions, Inc. (operating as Innovative Compounding Pharmacy) on September 19, 2018, regarding drug manufacturing and compounding practices. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. However, as a compounding pharmacy focused on intrathecal drug preparations, the violations likely relate to manufacturing quality, sterility, or compliance standards applicable to drug compounders. The warning falls under FDA's drug product regulatory authority.